Orthofix Medical Inc (NASDAQ:OFIX) CEO Brad Mason sold 5,805 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $50.97, for a total transaction of $295,880.85. Following the completion of the sale, the chief executive officer now owns 165,041 shares in the company, valued at approximately $8,412,139.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Brad Mason also recently made the following trade(s):

  • On Thursday, June 13th, Brad Mason sold 8,890 shares of Orthofix Medical stock. The shares were sold at an average price of $51.11, for a total transaction of $454,367.90.

OFIX stock opened at $50.34 on Friday. The firm has a market cap of $964.93 million, a PE ratio of 30.31, a P/E/G ratio of 2.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.26 and a current ratio of 3.42. The firm’s fifty day moving average is $51.52 and its 200 day moving average is $53.64. Orthofix Medical Inc has a one year low of $47.79 and a one year high of $74.44.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings results on Monday, August 5th. The medical device company reported $0.28 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by ($0.12). The firm had revenue of $115.85 million for the quarter, compared to analyst estimates of $115.17 million. Orthofix Medical had a net margin of 1.75% and a return on equity of 9.50%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.42 EPS. Research analysts predict that Orthofix Medical Inc will post 1.77 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in OFIX. BNP Paribas Arbitrage SA grew its position in Orthofix Medical by 185.5% during the first quarter. BNP Paribas Arbitrage SA now owns 4,576 shares of the medical device company’s stock valued at $258,000 after buying an additional 2,973 shares during the period. Arizona State Retirement System grew its position in shares of Orthofix Medical by 0.9% in the first quarter. Arizona State Retirement System now owns 29,404 shares of the medical device company’s stock valued at $1,659,000 after purchasing an additional 266 shares during the period. SG Americas Securities LLC grew its position in shares of Orthofix Medical by 54.3% in the first quarter. SG Americas Securities LLC now owns 18,168 shares of the medical device company’s stock valued at $1,025,000 after purchasing an additional 6,390 shares during the period. Menta Capital LLC acquired a new stake in shares of Orthofix Medical in the first quarter valued at about $288,000. Finally, Rhumbline Advisers grew its position in shares of Orthofix Medical by 1.5% in the first quarter. Rhumbline Advisers now owns 55,825 shares of the medical device company’s stock valued at $3,149,000 after purchasing an additional 810 shares during the period. Institutional investors own 93.63% of the company’s stock.

Several analysts recently commented on the stock. ValuEngine lowered shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. BidaskClub lowered shares of Orthofix Medical from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Zacks Investment Research lowered shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $59.50.

About Orthofix Medical

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.

Further Reading: Economic Bubble

Insider Buying and Selling by Quarter for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.